Company Filing History:
Years Active: 2001
Title: Elizabeth A. Austin: Innovator in Molecular Constructs
Introduction
Elizabeth A. Austin is a notable inventor based in Raleigh, NC (US). She has made significant contributions to the field of molecular biology, particularly in the development of innovative molecular constructs. Her work focuses on creating targeted therapies that can selectively affect cancerous cells.
Latest Patents
Elizabeth A. Austin holds a patent for "Molecular constructs comprising a carcinoembryonic antigen (CEA) transcriptional regulatory region." This patent describes novel molecular chimaeras produced by recombinant DNA techniques. These constructs comprise a target-tissue specific transcriptional regulatory sequence (TRS) linked to the expression of a heterologous enzyme, such as Varicella Zoster Virus Thymidine Kinase (VZV TK) or non-mammalian Cytosine Deaminase (CD). The molecular chimaera is packaged into a synthetic retroviral particle capable of infecting mammalian tissue. This allows for selective transcriptional activation in target tissues, such as cancerous cells, leading to the production of cytotoxic or cytostatic metabolites that can kill or arrest the growth of these cells.
Career Highlights
Elizabeth A. Austin is associated with Glaxo Wellcome Inc., where she has been instrumental in advancing research in molecular constructs. Her innovative approach has paved the way for new therapeutic strategies in cancer treatment.
Collaborations
Some of her notable coworkers include Brian Huber and Cynthia A. Richards. Their collaborative efforts have contributed to the success of various projects within the company.
Conclusion
Elizabeth A. Austin's work exemplifies the intersection of innovation and molecular biology, showcasing her commitment to developing targeted therapies for cancer treatment. Her contributions continue to influence the field and inspire future research.